Health
Adjuvant Anti-CDK Thwarts Early Breast Cancer Recurrence – MedPage Today
Risk of invasive recurrence declines 25% in patients with high-risk disease
Including a CDK4/6 inhibitor in adjuvant therapy significantly increased invasive disease-free survival (iDFS) in patients with high-risk early, hormone receptor (HR)-positive breast cancer, a large randomized trial showed.
The hazard for iDFS decreased by 25.3% with the addition of abemaciclib (Verzenio) to standard endocrine therapy. The risk of distant (metastatic) recurrence decreased by almost 30% with combination therapy as compared with endocrine therapy alone.
No new or unexpected toxi…
-
Noosa News20 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland
-
Business22 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Business20 hours agoThe best ASX shares to buy and forget for 10+ years
-
Noosa News23 hours agoBrisbane lawyer Christopher Saines dies unexpectedly after massage while on holiday in Thailand